Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis.
Amporndanai, K., Rogers, M., Watanabe, S., Yamanaka, K., O'Neill, P.M., Hasnain, S.S.(2020) EBioMedicine 59: 102980-102980
- PubMed: 32862101 
- DOI: https://doi.org/10.1016/j.ebiom.2020.102980
- Primary Citation of Related Structures:  
6Z3V, 6Z4G, 6Z4H, 6Z4I, 6Z4J, 6Z4K, 6Z4L, 6Z4M, 6Z4O - PubMed Abstract: 
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease as well as Lou Gehrig's disease, is a progressive neurological disorder selectively affecting motor neurons with no currently known cure. Around 20% of the familial ALS cases arise from dominant mutations in the sod1 gene encoding superoxide dismutase1 (SOD1) enzyme. Aggregation of mutant SOD1 in familial cases and of wild-type SOD1 in at least some sporadic ALS cases is one of the known causes of the disease. Riluzole, approved in 1995 and edaravone in 2017 remain the only drugs with limited therapeutic benefits.
Organizational Affiliation: 
Molecular Biophysics Group, Department of Biochemistry and System Biology, Institute of System, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, L69 7ZB, United Kingdom.